The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to ...

Popular weight-loss drugs like Ozempic and Zepbound have revolutionized how we tackle obesity. But now, emerging reports ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...